Cas:137314-93-3 Methanesulfonamide,N-(3-acetyl-4-fluorophenyl)- manufacturer & supplier

Chemical Name:Methanesulfonamide,N-(3-acetyl-4-fluorophenyl)-

CAS.NO:137314-93-3

Synonyms:N-(3-Acetyl-4-fluorophenyl)methanesulfonamide;Methanesulfonamide,N-(3-acetyl-4-fluorophenyl)-;Methanesulfonamide, N-(3-acetyl-4-fluorophenyl)-;3′-acetyl-4′-fluoromethanesulfonanilide

Molecular Formula:C₉H₁₀FNO₃S

Molecular Weight:231.244

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:356.8±52.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.557

PSA:71.62000

Exact Mass:231.036545

LogP:0.31

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(3-Acetyl-4-fluorophenyl)methanesulfonamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3′-acetyl-4′-fluoromethanesulfonanilide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(3-Acetyl-4-fluorophenyl)methanesulfonamide Use and application,3′-acetyl-4′-fluoromethanesulfonanilide technical grade,usp/ep/jp grade.

Related News: The researchers found that compared with those with cancer, the prevalence of FT was higher among those with ASCVD (54 versus 41 percent). In adjusted analyses, when studying individual components of FT, those with ASCVD had increased odds of any difficulty paying medical bills, inability to pay bills, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost (odds ratios, 1.22, 1.25, 1.28, 1.39, and 1.17, respectively). Methanesulfonamide,N-(3-acetyl-4-fluorophenyl)- manufacturer Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. Methanesulfonamide,N-(3-acetyl-4-fluorophenyl)- supplier In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. Methanesulfonamide,N-(3-acetyl-4-fluorophenyl)- vendor ��Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.�� Methanesulfonamide,N-(3-acetyl-4-fluorophenyl)- factory We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries.